Roche attempt to retool arthritis drug for coronavirus pneumonia fails trialChristian Fernsby ▼ | July 29, 2020
Roche announced that the phase III Covacta study of Actemra RoActemra tocilizumab did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe coronavirus associated pneumonia.
The Covacta study did not identify any new safety signals for Actemra RoActemra.
Further analysis of the trial results is needed to fully understand the data.
The results will be submitted for publication in a peer-reviewed journal. ■